Lipodystrophy is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

CLINICAL

  • Obesity is defined by body mass index (BMI) ≥30 kg/m2. In those with low body mass, BMI ranging from 18.5 to 24.9 kg/m2 may represent excess adiposity.[6]
    • Cause is multifactorial and includes imbalance between calories consumed and expended, age, genetics, and microbiome alterations.
    • Adipocyte plays central role in multisystem disease.[3]
  • Lipohypertrophy is localized abnormal fat accumulation: central or visceral adipose tissue (VAT), breast fat, dorso-cervical fat pad (buffalo hump) or lipomas.
    • Central adiposity is linked to increased mortality.[9]
      • VAT accumulation, as little as 5%, is associated with metabolic syndrome, diabetes, and cardiovascular disease (CVD).[6]
      • VAT, intrahepatic fat, and epicardial fat are associated with CVD, independent of traditional CVD risk factors.
    • Lipohypertrophy is associated with elevation of inflammatory cytokines.
  • Lipoatrophy (LA): peripheral fat loss in face, limbs and buttocks.
    • Consequence of thymidine analog NRTIs: d4T, ZDV. Switching ART prevents progression, but fat recovery slow and likely incomplete.
    • Can be confused with wasting, which is due to HIV disease progression and/or OIs, and includes both muscle and fat loss.
  • Lipodystrophy: coexisting lipohypertrophy and lipoatrophy with changes in body fat composition based on anthropomorphic measures of fat distribution, such as waist circumference (WC).
    • Accompanied by metabolic disorders: dyslipidemia, hypertriglyceridemia, low HDL, insulin resistance, and diabetes mellitus.
    • Low frequency (< 5%) with current ART regimens.

-- To view the remaining sections of this topic, please or --

CLINICAL

  • Obesity is defined by body mass index (BMI) ≥30 kg/m2. In those with low body mass, BMI ranging from 18.5 to 24.9 kg/m2 may represent excess adiposity.[6]
    • Cause is multifactorial and includes imbalance between calories consumed and expended, age, genetics, and microbiome alterations.
    • Adipocyte plays central role in multisystem disease.[3]
  • Lipohypertrophy is localized abnormal fat accumulation: central or visceral adipose tissue (VAT), breast fat, dorso-cervical fat pad (buffalo hump) or lipomas.
    • Central adiposity is linked to increased mortality.[9]
      • VAT accumulation, as little as 5%, is associated with metabolic syndrome, diabetes, and cardiovascular disease (CVD).[6]
      • VAT, intrahepatic fat, and epicardial fat are associated with CVD, independent of traditional CVD risk factors.
    • Lipohypertrophy is associated with elevation of inflammatory cytokines.
  • Lipoatrophy (LA): peripheral fat loss in face, limbs and buttocks.
    • Consequence of thymidine analog NRTIs: d4T, ZDV. Switching ART prevents progression, but fat recovery slow and likely incomplete.
    • Can be confused with wasting, which is due to HIV disease progression and/or OIs, and includes both muscle and fat loss.
  • Lipodystrophy: coexisting lipohypertrophy and lipoatrophy with changes in body fat composition based on anthropomorphic measures of fat distribution, such as waist circumference (WC).
    • Accompanied by metabolic disorders: dyslipidemia, hypertriglyceridemia, low HDL, insulin resistance, and diabetes mellitus.
    • Low frequency (< 5%) with current ART regimens.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 19, 2022